Home
LiteratureArticle Details
PMID: 15490497
Published · ppublish
English
Letter
Comment
Bevacizumab in colorectal cancer.
The New England journal of medicine
·Vol. 351
·No. 16
·2004-10-14
·Pages 1690-1; author reply 1690-1
Abstract
暂无摘要
MeSH Terms
Antibodies, Monoclonal/administration & dosage,adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols/adverse effects,therapeutic use
Bevacizumab
Camptothecin/administration & dosage,analogs & derivatives
Colorectal Neoplasms/drug therapy
Disease-Free Survival
Fluorouracil/administration & dosage
Humans
Irinotecan
Leucovorin/administration & dosage
Neoplasm Metastasis/drug therapy
Quality-Adjusted Life Years
Research Design
Chemicals
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab
Irinotecan
Leucovorin
Fluorouracil
Camptothecin
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
Published
2004-10-14
Pages
1690-1; author reply 1690-1
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
CommentOn
Analysis Services
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: [email protected]
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
